TransCode publishes preclinical data showing TTX-MC138 improves survival in glioblastoma models

Transcode Therapeutics, Inc.

Study in Journal of Functional Biomaterials shows TTX-MC138 delivered to GBM tumors after IV injection.
TTX-MC138 induced 5-fold increase in apoptotic activity and statistically significant survival extension.
IND-enabling studies completed; TTX-MC138 already in Phase 1a for metastatic solid tumors.
Phase 2a clinical trial for TTX-MC138 anticipated to begin in first half of 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.